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Abstract: Obesity is a major risk factor for diabetes, and these two metabolic conditions cause 
significant healthcare burden worldwide. Chronic inflammation and increased oxidative stress due 
to exposure of cells to excess nutrients in obesity may trigger insulin resistance and pancreatic β-
cell dysfunction. Tocotrienol, as a functional food component with anti-inflammatory, antioxidant, 
and cell signaling-mediating effects, may be a potential agent to complement the current 
management of obesity and diabetes. The review aimed to summarize the current evidence on the 
anti-obesity and antidiabetic effects of tocotrienol. Previous studies showed that tocotrienol could 
suppress adipogenesis and, subsequently, reduce body weight and fat mass in animals. This was 
achieved by regulating pathways of lipid metabolism and fatty acid biosynthesis. It could also 
reduce the expression of transcription factors regulating adipogenesis and increase apoptosis of 
adipocytes. In diabetic models, tocotrienol was shown to improve glucose homeostasis. Activation 
of peroxisome proliferator-activated receptors was suggested to be responsible for these effects. 
Tocotrienol also prevented multiple systemic complications due to obesity and diabetes in animal 
models through suppression of inflammation and oxidative stress. Several clinical trials have been 
conducted to validate the antidiabetic of tocotrienol, but the results were heterogeneous. There is 
no evidence showing the anti-obesity effects of tocotrienol in humans. Considering the limitations 
of the current studies, tocotrienol has the potential to be a functional food component to aid in the 
management of patients with obesity and diabetes. 
Keywords: adipose; diabetes; insulin resistance; metabolic syndrome; obesity; overweight;  
vitamin E 
 
1. Introduction 
Obesity is a multifactorial chronic medical condition affecting both children and adults 
worldwide. Clinically, the World Health Organization defines overweight as a body mass index 
(BMI) ≥ 25 kg/m2, and obesity as a BMI ≥ 30 kg/m2 in adults [1]. An estimate performed in 2015 found 
that 107.7 (98.7–118.7) million children and 603.7 (588.2–619.8) million adults suffered from obesity 
[2]. The abnormal or excessive fat accumulation in obese individuals poses adverse metabolic effects 
on their blood pressure, cholesterol, triglycerides levels, and glucose homeostasis [1,3]. 
Approximately 7.2% (4.9–9.4%) of all deaths and 4.9% (3.5–6.4%) of disability-adjusted-life-years 
(DALYs) worldwide in 2015 were attributable to excess body weight [2]. Of all deaths related to 
cardiovascular diseases, 41% was contributed by high BMI [2]. 
Obesity is a major risk factor of type 2 diabetes mellitus (T2DM). T2DM affects 463 million (424–
509 million) individuals worldwide and causes 37.6 million (255–520 million) years-lived-with-
disability in 2017 [4]. Uncontrolled T2DM can lead to complications in other organ systems, including 
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neuropathy, nephropathy, oculopathy, and cardiovascular diseases [5]. The exact mechanism that 
links obesity to T2DM is not clearly understood at this moment, but the exposure of cells towards 
concentration of nutrients exceeding energy requirement is suggested to play a role. This condition 
initiates the recruitment and activation of macrophages and other immune cells and invokes tissue 
inflammation. Concurrently, a high concentration of nutrients also causes mitochondrial dysfunction 
characterized by reduced mitochondrial mass and function. Both processes subsequently lead to 
insulin resistance in liver, skeletal muscle, and adipose tissue, as well as pancreatic β-cell dysfunction. 
The latter causes a drop in insulin production, which elevates circulatory glucose concentration, 
further worsening the problem of excessive nutrients [6]. The chronic inflammatory state and 
mitochondrial dysfunction also elevated oxidative stress in obese individuals, leading to impaired β-
cell regeneration and function [7,8]. 
The management of obesity involves behaviour and lifestyle modifications, including reducing 
calorie intake and increasing physical activity, to correct the calorie imbalance. Some medications, 
such as phentermine, lorcaserin, and orlistat, have been used to aid weight loss but they come with 
side effects. The effectiveness of bariatric surgery in weight management is gaining recognition, and 
it is the treatment of choice when the former methods fail [9]. The management of T2DM mainly 
involves the use of metformin and other hypoglycemic agents (sulfonylurea, pioglitazone, and 
dipeptidyl peptidase 4 inhibitor) to improve glycemic control [10]. For patients with obesity and 
T2DM, certain hypoglycemic agents may offset their efforts to reduce weight [11]. An agent that can 
help to manage obesity and T2DM concurrently would be very useful to patients suffering from both 
conditions. 
Tocotrienols (T3s) are among novel compounds studied extensively for their metabolic effects. 
Being in the vitamin E (tocochromanols) family, they share a similar structure with tocopherols, 
consisting of a 6-chromanol ring and a hydrophobic carbon side chain. T3s differ from tocopherols 
by the presence of three unsaturated bonds at the positions of 3, 7, and 11 of the side chains. This 
explains the better incorporation of T3s in the lipid membrane and intermembrane transfer. T3s can 
be further divided into α-, β-, γ-, and δ-isoforms based on the position of number and position of the 
methyl group at the chromanol ring [12,13]. The chemical structure of all tocopherol and T3 isoforms 
is shown in Figure 1. Both T3s and tocopherols are found in natural botanical sources in a mixture of 
varying composition as a natural defence mechanism against lipid peroxidation [12]. Some of the 
natural sources of T3 include annatto oil (34.27–36.25 mg/mL of the lipid extract from the seeds), palm 
oil (738 mg/mL), rice bran oil, RBO (586 mg/mL), and wheat germ (26 mg/mL) [14,15]. 
 
Figure 1. The chemical structure of four tocopherol and tocotrienol isoforms. 
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Many studies have established the role of T3 in protecting against metabolic, diabetic and 
cardiovascular pathologies [16,17]. Both animal and human studies report that T3 supplementation 
improves glucose homeostasis [18]. A limited number of animal studies suggested that T3 reduces 
body weight or body fat [19,20]. As a free radical scavenger, T3 can ameliorate oxidative stress in 
metabolic disorders and protect cellular functions [21]. T3 can suppress cholesterol synthesis by 
inhibiting 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR) post-transcriptionally, the 
rate-determining enzyme in the mevalonate pathway [22]. It has been shown to downregulate 
peroxisome proliferator-activated receptor γ (PPARγ)—the transcription factor critical in adipocytes 
differentiation [23]. It can prevent the activation of nuclear factor-κB (NF-κB), thereby halting tissue 
inflammation [24]. These biological activities suggest that T3 can be utilized in the management of 
metabolic conditions like obesity and T2DM. The objective of this review is to summarize current 
evidence on anti-obesity and antidiabetic effects of T3 derived from cellular, animal, and human 
studies. 
2. Literature Search 
The literature search was performed between the 1st and 25th May 2018 on PubMed and Scopus 
using the keywords “Obesity” or “Diabetes” and “Tocotrienol”. We also examined the reference lists 
of the retrieved articles. Original research articles regarding the beneficial effects of T3 and published 
in English were included. Studies of chemically modified T3 were excluded from this review. A total 
of 52 studies were included in the review.  
3. Tocotrienol and Obesity 
3.1. Anti-Obesity Properties of T3 
Adipogenesis refers to the differentiation of preadipocytes into mature adipocytes with 
increased synthesis and accumulation of intracellular triglyceride (TG) and lipid droplets [25,26]. T3 
was reported to exert anti-obesity properties on several cell lines [27–29]. It was demonstrated to 
suppress adipogenesis by reducing intracellular TG and lipid droplet accumulation in mouse 
hepatoma Hepa 1-6 cells [30], human hepatoma HepG2 cells [20,31], 3T3-L1 preadipocytes [27,32], 
3T3-F442A murine preadipocytes [23], and primary human adipose-derived stem cells (hASCs) 
[28,33] via oil red O staining assay. The potency of anti-adipogenic activities of T3 follows the order 
of γ-T3 > δ-T3 > β-T3 > α-T3 [27,28]. 
T3 was reported to reduce body weight, especially fat mass in several obese animal models 
[19,20,34–36]. A 20-week supplementation of rice bran enzymatic extract (RBEE) (5%) containing 174 
mg/kg T3 reduced body weight gain, visceral abdominal adipose tissue weight, and adipocyte size 
distribution in obese Zucker rats [34]. Similarly, oral administration of tocotrienol-rich fraction (TRF), 
with mixed T3 and tocopherol (120 mg/kg body weight, bw/day), also significantly reduced total 
abdominal omental fat pads in high fat diet-fed rats [36]. Oral γ-T3 supplementation (60 mg/kg) also 
significantly suppressed dexamethasone-induced obesity with lower body fat mass on 
adrenalectomized rats [37]. Besides, γ-T3 (0.05% in diet) also normalized high fat diet-induced weight 
gain by reducing adipose tissues gain in the epididymal fat pad, mesenteric fat pad, and liver of 
C57BL/6J mice [35]. In contrast, Wong et al. reported that δ-T3 (85 mg/kg bw/day), but not α-T3 and 
γ-T3, significantly reduced total fat mass, abdominal circumference, adiposity index, and 
retroperitoneal and epididymal fat pads mass in high carbohydrate/fat diet-fed rats [19]. On the other 
hand, T3 treatment (60 mg/kg/day) by gastric gavage marginally increased the mesenteric adipose 
tissues deposition in dexamethasone-treated adrenalectomized rats [38]. This discrepancy may be 
partly due to the composition or purity of T3 used. In addition, Tocomin® (palm tocotrienol mixtures, 
predominantly γ-T3) [21,39] and annatto oil T3 mixture (90% δ-T3 and 10% γ-T3) [40] were reported 
to have marginal effects on body weight and fat pad mass gain in high fat diet-fed rodents. To our 
best knowledge, there is no human study reported on the effect of T3 in preventing or reducing 
obesity. 
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3.2. Molecular Mechanism of Anti-Adipogenic Properties of T3 
3.2.1. Suppression of Adipogenesis by T3 
Mechanistically, T3 (TRF, δ-T3, γ-T3, or β-T3) was demonstrated to inhibit adipogenesis by 
upregulating the lipid metabolism proteins/enzymes including carnitine palmitoyltransferase 1A/2 
(CPT1A/2), Forkhead box A2 (FOXA2), cytochrome P450 3A4, adiponectin receptor protein 2 
(ADIPOR2), uncoupling protein 2 (UCP2), and peroxisome proliferator-activated receptor α/δ 
(PPARα/δ) [20,27,30,40]. At the same time, T3 was also shown to downregulate fatty acid biosynthesis 
proteins/enzymes, including fatty acid synthase (FAS), sterol regulatory element-binding protein-1/2 
(Srebf1/2), stearoyl-CoA desaturase-1 (Scd1), acetyl-CoA carboxylase-1 (ACC1), HMGCR, 
apolipoprotein, low-density lipoprotein receptor (LDLR), diglyceride acyltransferase (Dgat2), 
pyruvate kinase, and carbohydrate-responsive element-binding protein (ChREBP) 
[20,27,30,31,33,40].  
Studies also showed that T3 inhibited adipogenesis via downregulation of adipogenic 
transcription factors expression and/or signaling, including Akt [23,32], CCAAT-enhancer-binding 
protein α (C/EBPα) [28,32,33] and PPARγ signaling [27–29,32,33]. Besides, T3 was also demonstrated 
to downregulate PPARγ downstream genes expression including fatty acid binding protein (FABP), 
adiponectin, glucose transporter type 4 (Glut4), perilipin, and hormone-sensitive lipase (HSL) 
[23,28,32,33]. In addition, TRF and γ-T3 (but not α-T3) significantly suppressed FABP and C/EBPα 
mRNA expression upon insulin stimulation in 3T3-L1 preadipocytes [32]. TRF (1 µM), α-T3 (0.24 
µM), and γ-T3 (0.024 µM) were also reported to reduce insulin-mediated upregulation of PPARγ 
mRNA level during the differentiation of 3T3-L1 preadipocytes [32]. γ-T3 but not α-T3 significantly 
suppressed insulin-mediated PPARγ protein expression, Akt activation, and adipogenesis in 3T3-L1 
preadipocytes [32]. Another similar study also revealed that δ-T3 suppressed adipogenesis of 3T3-
F442A preadipocytes with the reduction of HMGCR expression and suppression of Akt and PPARγ 
signaling [23]. Molecular experiment further revealed that the antiadipogenic effect of δ-T3 was 
independent of HMGCR inhibition [23]. Rosiglitazone (PPARγ agonist), but not mevalonolactone 
(the product of HMGCR signaling), managed to revert δ-T3-suppressed preadipocyte differentiation 
[23]. Interestingly, Zhao et al. reported that γ-T3 and δ-T3 did not exert significant anti-adipogenic 
activities on the terminal and fully differentiated adipocytes [28]. Similarly, Matsunaga et al. also 
reported that γ-T3 restored tumor necrosis factor-α (TNF-α)-downregulated adiponectin and PPARγ 
mRNA levels in differentiated 3T3-L1 cells [41]. This may explain the inconsistent findings of T3-
suppressed fat mass gain in different cells or obesity model. 
3.2.2. Pro-Apoptotic Effects of T3 on Adipocytes 
On the other hand, T3 also exhibits anti-adipogenic activities by causing adipocyte cell death 
[27–29]. α-T3, γ-T3, and δ-T3 (10 and 20 µM) were reported to induce anti-adipogenesis via 
antiproliferation and apoptosis induction on 3T3-L1 preadipocytes [29]. Besides, all T3 isoforms were 
cytotoxic to 3T3-L1 preadipocytes at a concentration of 30–50 µM [27]. Furthermore, Zhao et al. 
reported that γ-T3 and δ-T3 but not α-T3 were cytotoxic to undifferentiated (5 µM) and differentiated 
(10 µM) primary hASCs [28]. The negative finding of α-T3 might be due to the much lower 
concentration used in this study. In addition, γ-T3 also induced autophagy in primary hASCs [28], 
however, it might not directly relate to the anti-adipogenic activity [28]. In apoptosis induction, γ-T3 
was reported as the most potent apoptosis inducer on undifferentiated 3T3-L1 preadipocyte [29]. 
However, Burdeos et al. reported that δ-T3 was the most potent cytotoxicity inducer on differentiated 
3T3-L1 adipocytes, followed by γ-T3, β-T3, and α-T3 [27]. This discrepancy in potency was possibly 
due to the different stage of adipocytes used in cytotoxicity testing. Further study is required to 
confirm the potency of T3 isoforms in apoptosis induction. 
Molecular mechanisms of T3-induced (mainly γ-T3) adipocyte apoptosis was also investigated 
[28,29]. γ-T3-induced 3T3-L1 preadipocytes apoptosis required 5’-adenosine monophosphate-
activated protein kinase (AMPK) signaling, downregulation of B-cell lymphoma-2 (Bcl-2), PPARγ, 
Akt and extracellular signal-regulated kinase (ERK) signaling, upregulation of Fas ligand and Bcl-2-
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associated x protein (Bax) expression, and activation of caspase-3 and c-Jun N-terminal kinase (JNK) 
signaling [29]. γ-T3 induced hASCs apoptosis with increased Bax/Bcl-2 ratio, caspase-3 activation, 
and karyorrhexis [28]. Molecular ordering analysis further revealed that γ-T3 modulated the 
nutrient-sensing pathways by activating AMPK but inhibiting Akt signaling in the early phase of 
treatment [28]. Inhibition on Akt signaling subsequently interfered with mammalian target of 
rapamycin (mTOR) and its downstream signaling in hASCs [28]. Activation of AMPK signaling is 
crucial in anti-adipogenic activities of γ-T3, whereby inhibition of the AMPK pathway partially 
reversed the γ-T3-induced anti-adipogenic effect [28]. In addition, AMPK inhibition did not alter γ-
T3-induced autophagy which suggested that autophagy might not directly relate to the anti-
adipogenic activity of γ-T3 [28]. 
3.3. Other Beneficial Effects of T3 on Obesity Management 
3.3.1. Anti-Inflammatory Activity of T3 
Obesity is closely associated with low-grade inflammation, which subsequently increases the 
risk of cardiovascular diseases, metabolic syndrome, insulin resistance, and diabetes mellitus [42]. 
Anti-inflammatory properties of T3 were reported in several cell lines and obesity animal models 
[33–35,40,43,44]. T3 in RBEE (5%) [34], muscadine grape seed oil (MGSO) [33], TRF from MGSO [33], 
annatto oil T3 mixture [40], and γ-T3 [35,41,44] were reported to suppress the release and expression 
of pro-inflammatory mediators including TNF-α, granulocyte colony-stimulating factor (G-CSF), 
C/EBPβ, leptin hormone, interleukin-1β (IL-1β), interleukin-6 (IL-6), interleukin-8 (IL-8), inducible 
nitrite oxide synthase (iNOS), and/or monocyte chemotactic protein-1 (MCP-1). Lower concentrations 
of γ-T3 (0.024-2.4µM) also resulted in partial suppression of TNF-α-upregulated MCP-1 and IL-6 
expression with the restoration of adiponectin and PPARγ expression in differentiated 3T3-L1 cells 
[41]. Besides, annatto oil T3 mixture was also reported to upregulate anti-inflammatory cytokine 
interleukin 10 (IL-10) mRNA levels in the adipose tissue of high-fat diet-fed C57BL/6J mice [40]. In 
addition, annatto oil T3 mixture [40] and γ-T3 (0.05% diet) [35] also significantly reduced macrophage 
infiltration in the adipose tissue of obese mice.  
Besides, T3, especially γ-T3, also serves as a potent NF-κB inhibitor [43]. γ-T3 is the most potent 
NF-κB inhibitor compared to other T3 isoforms via electrophoretic mobility shift assay [43]. γ-T3 (5–
25 µM) suppressed transforming growth factor β-activated kinase 1 and receptor-interacting protein-
induced NF-κB-dependent reporter gene expression in a concentration-dependent manner [43]. 
Besides, γ-T3 (25 µM) also completely abrogated TNFα-induced NF-κB activation in human lung 
adenocarcinoma H1299 cells, human embryonic kidney A293 cells, human breast cancer MCF-7 cells, 
human multiple myeloma U266 cells, and human squamous cell carcinoma SCC4 cells [43]. 
Furthermore, γ-T3 also abrogated the NF-κB activation by TNFα, phorbol myristate acetate (PMA), 
okadaic acid, lipopolysaccharide (LPS), cigarette smoke condensate (CSC), IL-1β, and epidermal 
growth factor (EGF) in human myeloid leukaemia KBM-5 cells [43]. Subsequently, γ-T3 
downregulated the NF-κB downstream gene products associated with cancer cell survival, 
proliferation, invasion and angiogenesis [43].  
Mechanistically, γ-T3 inhibited NF-κB activation by suppressing the upstream nuclear factor-κB 
inhibitor type α kinase (IKK) and Akt signaling, which subsequently suppressed the nuclear factor-
κB inhibitor type α (IκBα) degradation and NF-κB p65 nuclear translocation [35,41,43,44]. In addition, 
γ-T3 was reported to suppress mitogen-activated protein kinases (MAPKs) activation including JNK, 
p38, and ERK in LPS-stimulated hASCs [35]. In contradiction, Wang et al. reported that γ-T3 did not 
suppress LPS-induced TNF-α, IL-10, cyclooxygenase 2 (COX-2) upregulation, or p38 activation in 
RAW 264.7 macrophages [44]. This discrepancy may be attributable to the study models used, thus 
warrant further studies to confirm the role of MAPKs in the anti-inflammatory effects of γ-T3.  
3.3.2. Effects of T3 on Glycemic Status and Insulin Sensitivity in Obesity Models 
T3, especially γ-T3 and δ-T3, were demonstrated to improve glycemic control on several in vitro 
models [35,45] and diet-induced obesity animal models [19,35,36,40]. However, no human study on 
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the effect of T3 on glycemic control in the obese population has been reported. In vitro studies showed 
that γ-T3 restored the glucose uptake, insulin sensitivity, and Akt signaling in differentiated primary 
mouse adipocytes [45] and primary hASCs [35]. Palm TRF [36] and δ-T3-enriched palm olein [19] 
were reported to normalize the fasting blood glucose level and improve the postprandial glucose 
utilization in high fat-fed rats. Besides, annatto oil T3 mixture (90% δ-T3 and 10% γ-T3) also 
significantly improved glucose tolerance upon intraperitoneal glucose injection without any 
alteration of serum insulin level in high fat diet-fed C57BL/6J mice [40]. γ-T3 (0.05% in the diet) also 
normalized blood fasting glucose and insulin levels as a result of enhanced insulin signaling (Akt 
and insulin receptor subunit-1 (IRS-1) activation) in high fat diet-fed mice [35]. It is noteworthy that 
T3 inhibited Akt signaling in undifferentiated 3T3-L1 preadipocytes [23,29,32] but not on 
differentiated adipocytes [45], differentiated primary hASCs [35], and animal models [35,46]. This 
biphasic response based on the different stages of adipocyte differentiation should be investigated 
further. Apart from this, palm T3 treatment (60 mg/kg/day; unknown composition) was 
demonstrated to downregulate 11β-hydroxysteroid dehydrogenase 1 (steroid hormone metabolism 
enzyme) expression in mesenteric adipocytes of dexamethasone-treated adrenalectomized rats, 
which might explain its hypoglycemic effect [38].  
On the other hand, Betik et al. reported that 50 mg/kg bw/day of T3 supplement (Tocomin®) for 
10 weeks did not significantly alter the pre- and post-exercise intraperitoneal glucose tolerance and 
insulin sensitivity in Sprague Dawley rats [39]. Similarly, 4-week subcutaneous administration of 
Tocomin® did not significantly alter the blood glucose and glycated hemoglobin (HbA1c) levels in 
high fat-diet rats [21]. The purity and composition in Tocomin® may partly explain the negative 
findings in these studies compared to the others with more promising results. 
3.3.3. The Effects of T3 on Liver and Lipid Profile 
Obesity is a strong risk factor for nonalcoholic liver disease due to abnormalities in lipid 
metabolism and local and systemic inflammation, which altogether impair liver function [47]. T3 was 
reported to improve liver profile in obesity models [19,36,40] Palm TRF [36], α-T3, γ-T3, or δ-T3-
enriched palm olein (85 mg/kg bw/day) [19] were demonstrated to reduce liver injury in diet-induced 
obese Wistar rats by reducing liver injury markers including plasma aspartate transaminase (AST) 
and alanine transaminase (ALT) levels. In addition, annatto oil T3 mixture (400 and 1600 mg/kg) also 
suppressed hepatic steatosis and decreased the liver lipid droplets in diet-induced obese C57BL/6J 
mice [40]. Annatto oil T3 mixture also significantly reduced liver inflammation of obese mice, 
indicated by lower TNF-α mRNA level [40]. Parallel with this, TRF, α-T3, γ-T3, and δ-T3 also 
attenuated hepatic steatosis and inflammatory cells infiltration in the liver of obese rats [19,36]. There 
is accumulated evidence demonstrating that hepatic PPARα activation is closely related to the 
reduction of hepatic inflammation [48]. PPARδ activation was also demonstrated to promote anti-
inflammatory gene expression [48,49]. Therefore, it is logical to suggest that T3 reduces hepatic 
inflammation and injury via PPARα/ δ activation. Moreover, T3 also improved blood lipid profile in 
several obese animal models [19,20,31,36,40]. T3 treatment, including palm TRF [36] (mixture of 
several T3s and tocopherol isoforms), T3-rich RBO (5 or 10 mg/day) [20], annatto oil T3 mixture [40], 
and δ-T3-enriched palm olein (85 mg/kg bw/day) [19] significantly reduced blood TG and 
nonessential fatty acid level in high fat diet-fed rodents. Intraperitoneal injection of γ-T3 (1 mg/day) 
also reduced blood TG, total cholesterol (TC) and low-density lipoprotein (LDL) level in LDLR–null 
C57BL/6 mice with no sign of toxicity [31].  
A beneficial effect of T3 on the lipid and/or liver profiles of the obese population has not been 
reported so far. Two double-blind placebo-controlled clinical trials were conducted on 
hypercholesterolemic subjects [31,50]. T3 mixture (120 mg/day; 60 mg for each δ-T3 and γ-T3) 
managed to reduce TG and chylomicron level on 40 hypercholesterolemic subjects [31]. T3 
supplementation (123 mg α-T3, 225.6 mg γ-T3, 51.4 mg δ-T3, and 122.2 mg α-tocopherol) for 1 year 
caused a marginal improvement on the liver echogenic response and ultrasound examination on 
these subjects with mild hypercholesterolaemia and nonalcoholic fatty liver [50]. T3 mixture did not 
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improve their glycemic status, lipid profile, liver profile, and renal profile [50]. This study might be 
limited by the small sample size and further study is required to confirm the findings. 
3.3.4. Cardioprotective Effects of T3 
Several experiments were conducted to investigate the beneficial effect of Tocomin® [21], palm 
TRF [36], and purified T3 isoforms [19] in improving the cardiovascular function in obese animal 
models. Oral administration of palm TRF significantly normalized the systolic blood pressure and 
improved the noradrenaline-induced thoracic aortic contraction in high-fat-diet-fed rats [36]. TRF 
also improved systolic function, reduced cardiac eccentric hypertrophy, and diastolic stiffness [36]. 
Histopathological examination further revealed that TRF inhibited the inflammatory cells infiltration 
and collagen deposition in the left ventricle of rats [36]. However, palm TRF had no effect on sodium 
nitroprusside and acetylcholine-induced thoracic aortic relaxation [36]. Similarly, subcutaneous 
administration of Tocomin® (40 mg/kg/day) also significantly improved Nω-nitro-L-arginine methyl 
ester (L-NAME, an inhibitor of endothelial nitric oxide synthase (eNOS))-induced contractile 
response of rat aorta [21]. Tocomin® also improved the sensitivity of acetylcholine but not sodium 
nitroprusside-induced rat aorta relaxation [21]. Tocomin® induced aortic relaxation via eNOS/soluble 
guanylate cyclase (sGC)-independent release of endothelial NO [21]. Besides, Tocomin® was 
demonstrated to restore eNOS and calmodulin (eNOS activator) expressions, Akt signaling and to 
reduce diet-induced upregulation of caveolin 1 (eNOS suppressor) expression [21]. In addition, 
Tocomin® also reduced superoxide production in rat aorta via the reduction of nicotinamide adenine 
dinucleotide phosphate oxidase 2 (Nox2) expression [21]. Moreover, γ-T3- and δ-T3-enriched (but 
not α-T3) palm olein (85 mg/kg bw/day) improved cardiovascular function by reducing eccentric 
hypertrophy and normalize systolic blood pressure in diet-induced obese rats [19]. α-T3, γ-T3, and 
δ-T3 significantly reduced the collagen deposition and inflammatory cell infiltration in the heart 
muscles [19]. γ-T3 and δ-T3 also improved the thoracic aortic contraction responses to noradrenaline 
[19]. Contradictory to the previous study [36], γ-T3 and δ-T3 were reported to improve the sodium 
nitroprusside and acetylcholine-induced relaxation in isolated thoracic aortic rings [19]. Further 
study is required to confirm these findings.  
Figure 2 summarizes the beneficial effects of T3 on obesity from the current cell culture, 
preclinical and clinical findings. 
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Figure 2. The beneficial effects of tocotrienol on obesity from cell culture, preclinical, and clinical 
studies. Abbreviations: ↑ = increase or upregulate, ↓ = decrease or downregulate, LDL = low-density 
lipoprotein, NF-κB = nuclear factor-κB, PPARγ = peroxisome proliferator-activated receptor γ, TG = 
triglyceride, TC = total cholesterol. 
4. Tocotrienol and Diabetes Mellitus 
4.1. Antidiabetic Properties of T3 in Cell Lines and Diabetic Animals 
Diabetes is closely associated with obesity due to increased insulin resistance and β cell 
dysfunction as illustrated previously. Several studies concerning the glucose-regulating effects of T3 
in obese animal models have been discussed in the previous section. This section will take a closer 
look at the effects of T3 on diabetes and its complications.  
A multitude of animal studies demonstrated the antidiabetic properties of T3, especially γ-T3 
and δ-T3, by preventing diabetic weight loss, hyperphagia, and polydipsia in type-1 diabetes mellitus 
Molecules 2019, 24, 923 9 of 24 
 
(T1DM) and T2DM models [45,46,51,52]. Besides, T3 (individual isoform or TRF) significantly 
improved the glycemic status of diabetic animals by reducing blood glucose level and HbA1c level 
[45,46,51–61]. In addition, the combination treatment of TRF and insulin resulted in better glycemic 
control in T1DM rats as compared to single treatment [51,52,57]. 
Mechanistically, T3 improved glycemic control in diabetic animals by improving insulin 
synthesis (insulinotropic activity) [45,61] and enhancing insulin sensitivity [45,46,60]. Chia et al. 
reported that T3 isoforms, including α-T3, γ-T3, and δ-T3, demonstrated insulinotropic activities [61]. 
δ-T3 is the most potent isoform with insulinotropic activity, followed by γ-T3 and α-T3 [61]. Insulin 
release genes, including insulin 1 (INS-1) and glucose transporter type 2 (GLUT2), and insulin gene 
transcription factors (PDX1, MafA, and BETA2), were upregulated in T3 isoform-treated glucose-
stimulated primary normal rat pancreatic β-islet cells [61]. Moreover, cotreatment of T3 isoforms with 
potassium chloride further enhanced the INS-1 gene expression [61]. Another similar study by Lee et 
al. also reported the insulinotropic activities of γ-T3 (1g/kg diet), whereby γ-T3 significantly 
suppressed the progression of diabetes in BKS.Cg-Dock7m+/+ Leprdb/J mice (db/db mice) by reducing 
the fasting blood glucose level and increasing adiponectin level [45]. Besides, γ-T3 also enhanced the 
clearance of intraperitoneally injected glucose with a two-fold increase of plasma insulin level in 
diabetic db/db mice [45]. The histological analysis further revealed that γ-T3 attenuated the loss of 
pancreatic β-cells and delayed the progression of diabetes in db/db mice by increasing the average 
islet size, size distribution, and insulin-positive area with a lower degree of immune cell infiltration 
[45].  
TRF from palm oil (21.8% α-tocopherol, 1.0% γ-tocopherol, 23.4% α-T3, and 37.4% γ-T3) was 
demonstrated to improve insulin sensitivity by lowering homeostatic model assessment estimated-
insulin resistance (HOMA-IR) in high fat-diet and streptozotocin (STZ)-induced diabetic C57BL/6J 
mice [46]. This effect was attributed to the ability of TRF in restoring the IRS-1 expression, Glut4 
expression, and Akt signaling in skeletal muscle of these diabetic mice [46]. Besides, another similar 
study from Fang et al. also reported that TRF diet (50 mg/kg) improved insulin sensitivity by 
upregulating PPAR and uncoupling protein 3 (UCP3) mRNA level in the muscles of non-fasting 
T1DM male C57BLKS/J-Lepr Db/Db mice [60]. PPARα was potently activated upon TRF treatment, 
followed by PPARγ and PPARδ [60]. In addition, purified α-T3 and γ-T3 were reported to serve as a 
PPARα-selective agonist by activating PPARα [60]. Purified δ-T3, on the other hand, served as pan-
PPAR agonist where it greatly activated PPARα and partially activated PPARγ and PPARδ [60]. 
Furthermore, the molecular analysis also revealed that α-T3, γ-T3, and δ-T3 served as direct PPARα 
agonist by enhancing the interaction between PPARα and PPARγ coactivator-1α (PGC-1α) in a dose-
dependent manner [60]. Parallel with the reporter assay, δ-T3 also demonstrated a greater potency in 
enhancing PPARα-PGC-1α interaction as compared to others [61]. Molecular docking analysis also 
demonstrated that δ-T3 exhibited higher affinity and formed greater H-bonding interaction with 
PPARδ and PPARγ as compared to α-T3, thus explaining its pan-PPAR agonist properties [61]. In 
addition, α-T3, γ-T3, and δ-T3 were also reported to upregulate PPARδ and PPARγ mRNA level in 
glucose-stimulated primary pancreatic β-islet cells in normal rats [61]. Parallel with the molecular 
studies, δ-T3 did not possess any direct antidiabetic activity where it was reported only weakly 
reduced the accumulation of AGE products with IC50 more than 3 mM in a cell-free anti-AGE assay 
[62]. Interestingly, T3s, including TRF and the purified isoforms, were reported to downregulate 
PPARγ in obesity studies but oppositely upregulate and activate PPARγ in diabetic models. We 
suggested these interesting outcomes may relate to the differential actions of T3 in different stages of 
disease or types of cells. Parallel with this, the known antidiabetic drug thiazolidinedione (PPARγ 
agonist) was reported to induce treatment-related fat gain via PPARγ activation [63,64]. 
On the other hand, several negative findings of T3 on the glycemic control of diabetic animals 
were reported [62,65–67]. Combination of 0.1 g/kg diet T3 mixtures (22.4% α-T3, 1.6% β-T3, 20.8% γ-
T3, and 10.1% δ-T3) with astaxanthin (natural carotenoid) did not reduce serum glucose and HbA1c 
levels in STZ-induced diabetic Osteogenic Disorder Shionogi rats [66]. In addition, Chou et al. 
demonstrated that RBO diet (15%), which contains 0.9 g of γ-T3, did not significantly alter the plasma 
glucose and insulin level [67]. Kaup et al. further showed that γ-T3 did not exert any insulinotropic 
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activity in glucose-stimulated INS-1 cells despite very high concentration (100 mg/mL) [65]. These 
negative findings also partially indicate that only certain T3 isoforms (for instance δ-T3) possess 
significant antidiabetic activities.  
4.2. Antidiabetic Activities of T3 in Human Studies 
Findings on the antidiabetic effects of T3 on humans are heterogeneous. The Finnish Mobile 
Health Examination Survey, with 23-year follow-up, was conducted to investigate the association 
between dietary intake of T3 isoforms and the risk of T2DM in 2285 men and 2019 women aged 40–
69 years old and free from diabetes at baseline [68]. The result showed that only dietary intake of β-
T3 was significantly associated with the lower risk of T2DM [68]. The negative finding of other T3 
may due to their extremely low dietary intake [68]. Among all T3 isoforms, intake of β-T3 was the 
highest (2.2 mg/day) [68]. However, this cohort study was limited by its small diabetes case size (383 
cases) [68]. Another randomized, double-blind, and placebo-controlled cohort study—Alpha-
Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study—on 29,133 male Finnish smokers (aged 
50–69 years old) also reported similar findings [69]. The median follow-up period of this study was 
10 years and it had a larger case size (660 cases of T2DM) among 25,505 subjects with complete dietary 
data [69]. The result showed that only dietary β-T3 was positively associated with lower risk of T2DM 
[69]. Similar to the earlier study, the dietary intake of β-T3 was the highest among T3 isoforms [69]. 
This association, however, was found to be insignificant upon adjustment for demographic factors 
[69]. Nevertheless, this cohort study was limited by recall bias and dietary changes during the study 
period [69].  
Several studies showed that supplementation of T3 resulted in better glycemic control on 
diabetes patients [70,71]. T3-enriched canola oil (200 mg/day) supplied to 45 T2DM patients was 
demonstrated to reduce their fasting blood glucose level [70]. The randomized controlled trial (RCT) 
of Vitamin E in Neuroprotection Study (VENUS) was conducted from 2011 until 2015 to identify the 
effects of T3 on glycemic control and neuroprotection [71]. Among the 229 diabetic patients who 
completed this trial, oral supplementation of mixed T3 (400 mg/day) for 1 year was shown to improve 
their glycemic control. However, it did not reduce neuropathic symptoms of diabetes among the 
patients [71]. The dose of 400 mg T3 per day was considered safe for a human with no observed 
adverse effect [71]. 
Wan Nazaimoon et al. supplemented 32 T1DM patients with 1800 mg of a tocotrienol-rich 
extract, Palmvitee (4% tocopherol and 16% T3 or equivalent to 288 mg T3) or refined palm oil (<0.1% 
T3) capsules daily for 60 days, followed by a washout period of 60 days and crossed over the 
treatment for another 60 days [72]. The result showed that both Palmvitee and refined palm oil did 
not improve the glycemic status of T1DM patients with plateau HbA1c levels [72]. Similarly, a 
double-blinded and placebo-controlled RCT was conducted on 19 T2DM patients with 
hyperlipidemia. The subjects received either placebo or a TRF treatment (6 mg/kg body mass/day for 
60 days) comprising of 14.6% α-T3, 2.2% β-T3, 38.8% γ-T3, and 2.4% unidentified T3 [73]. The result 
showed that TRF did not significantly alter the fasting and postprandial glucose level, as well as the 
glycated hemoglobin level in these T2DM patients [73]. In another RCT, TRF from palm oil (24.5% α-
T3, 3.5% β-T3, 35.4% γ-T3, 12.7% δ-T3, and 23.9% α-tocopherol) was orally administrated (552 
mg/day) to 86 T2DM patients for eight weeks [74]. It also did not improve the glycemic status of these 
patients because the HbA1c, serum insulin, plasma glucose levels, and HOMA-IR values were 
unchanged [74]. The authors suggested that these T2DM patients (both placebo and treatment group) 
were glycemically stable with a borderline abnormal value of glucose, glycated hemoglobin and 
serum adiponectin levels [73,74], which might explain the lack of hypoglycemic effect of TRF.  
The effects of T3 in improving diabetes and diabetic-related complications in human studies are 
summarized in Table 1. 
4.3. Effects of T3 in Diabetes-Mediated Lipid Abnormalities 
Hyperglycemia in T2DM is frequently associated with increased risk of hyperlipidemia, 
hypercholesterolaemia, hypertriglyceridemia, and hyperinsulinemia [75,76]. These lipid 
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abnormalities are prevalent in diabetes patients due to insulin resistance or alteration of lipid 
metabolism pathway [75]. Several studies reported that T3 reduced lipid abnormalities in diabetic 
animals [54,56,59,67]. TRF from palm oil (200 mg/kg bw/day) [54,56] and RBO (400 mg/kg bw/day) 
[54] were reported to improve lipid profile by restoring the serum high-density lipoprotein 
cholesterol (HDL-C) level and suppressing the increased serum TC, TG, low-density lipoprotein 
cholesterol (LDL-C), and very low-density lipoprotein cholesterol (VLDL-C) levels in diabetic rats. 
Besides, low dose of γ-T3 (0.6 mg/g) in the RBO diet also significantly suppressed hyperlipidemia via 
reduction of plasma and hepatic TG and LDL-C levels in STZ-induced T2DM rats [59]. Another 
similar study from Chou et al. demonstrated that high dose of γ-T3 (6 mg/g) in RBO diet also 
increased HDL-C level and reduced nonesterified fatty acid, liver cholesterol, and TC to HDL-C ratio 
in T2DM rats [67]. This γ-T3-enriched RBO also significantly increased plasma and liver saturated 
fatty acid and monounsaturated fatty acid levels with a lower level of polyunsaturated fatty acid [67]. 
However, this γ-T3-enriched RBO diet did not significantly reduce TC, LDL-C, and TG level [67]. In 
addition, γ-T3-enriched RBO diet increased faecal neutral sterols and bile acid excretion in diabetic 
rats [59,67] and upregulated hepatic cholesterol 7α-hydroxylase, LDLR, and HMGCR expression [59]. 
This is contradictory to the previous studies which reported that T3 downregulated HMGCR 
expression and activity [77,78]. It is possible that T3 suppression of mevalonate pathway leads to an 
adaptive response in the liver of the treated rats by increasing HMGCR expression. 
TRF was demonstrated to reduce serum total lipids, TC, and LDL-C levels of 19 T2DM patients 
with hyperlipidemia in one randomized, double-blinded and placebo-controlled trial [73]. However, 
TRF did not alter the levels of VLDL-C, HDL-C, and TG in these T2DM patients [73]. From human 
studies, T3-rich extract, Palmvitee (1800 mg/day) was administrated to 32 T1DM patients [72]. 
Palmvitee did not improve the lipid profile of T1DM patients where the TC, TG, HDL, and LDL levels 
remained unchanged [72]. In another RCT study, oral administration of TRF from palm oil (552 
mg/day) did not improve the lipid profile of 86 T2DM patients, whereby serum TC, TG, HDL-C, LDL-
C, and TC/LDL-C ratio were unaltered [74]. This warrants further investigation in confirming the 
effects of T3 on lipid profile. The negative changes in lipid profile associated with high-dose T3 
supplementation suggest that its effects might be U-shaped.  
4.4. Anti-Inflammatory Effects of T3 in Diabetic Models 
The anti-inflammatory properties of T3 have been investigated extensively [79]. However, there 
is limited evidence to demonstrate the direct anti-inflammatory action of T3 in diabetic animal or 
human models. TRF was shown to normalize the inflammation-related markers including NF-κB, 
MCP-1, IL-6, and TNF-α in the skeletal muscle of STZ-induced diabetic C57BL/6J mice [46]. Besides, 
γ-T3 was demonstrated to inhibit the downstream activation of caspase-1 and the release of IL-1β 
and IL-18 in isolated peritoneal macrophages from diabetic db/db mice upon stimulation of palmitate 
(inflammasome activator) and LPS [45]. A similar finding was reported on γ-T3-treated nigericin 
(inflammasome activator) and LPS-stimulated iJ774 macrophages and primary bone marrow-derived 
macrophages (BMDMs) from C57BL/6 mice [45]. Mechanistically, suppression of caspase-1 activation 
and IL-1β secretion by γ-T3 were found to be dependent on nucleotide-binding oligomerization 
domain-like receptor protein 3 (NLRP3) inflammasome suppression but independent on A20 (a 
negative regulator of NF-κB) [45]. In addition, anti-inflammatory actions of γ-T3 also involved AMPK 
signaling. This is evidenced by the almost complete reversal of γ-T3’s suppression of NLRP3 
inflammasome activity, caspase-1 activation and IL-1β secretion in palmitate and LPS-stimulated 
iJ774 macrophages by compound C (AMPK inhibitor) [45]. Moreover, γ-T3 also induced early 
blockage of NF-κB activation by promoting nonproteasomal degradation of tumor necrosis factor 
receptor-associated factor 6 (TRAF6; positive regulator of NF-κB) [45]. On the other hand, two 
double-blinded randomized controlled trials were conducted to investigate the effect of T3 on the 
inflammatory status of diabetes patients [74,80]. T3-enriched canola oil (200 mg/day) was supplied to 
44 T2DM patients for eight weeks [80]. This T3 supplement consists of 13.2% α-T3, 16.6% γ-T3, 8.6% 
other unspecified T3, and 16% α-tocopherol [80]. The result showed that T3-enriched canola oil 
significantly reduced serum high sensitivity-C reactive protein (hsCRP) in T2DM patients [80]. In 
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another recent RCT study, oral administration of TRF from palm oil (552 mg/day) did not improve 
the inflammatory status of these T2DM patients, in which serum inflammatory markers, including 
hsCRP, IL-6, and TNF-α, were unchanged [74]. 
4.5. Antioxidant Properties of T3 in Diabetic Animal Models 
Oxidative–nitrosative stress is involved in the pathogenesis of diabetes mellitus [81,82]. 
Hyperglycemia was closely related to the upregulation of reactive oxygen species/reactive nitrogen 
species (ROS/RNS) [83,84]. This oxidative–nitrosative stress subsequently contributes to diabetic 
cardiovascular disease, retinopathy, neuropathy, and nephropathy [85–87]. In this situation, 
antioxidants including T3 might be beneficial in diabetes management. T3 was demonstrated to 
reduce oxidative–nitrosative stress in several diabetic animal models as indicated by the reduction of 
biomarker for oxidative stress including total nitric oxide (NO), malondialdehyde (MDA), and 4-
hydroxynonenal (4-HNE) level as well as the restoration of nonthiol-protein expression and 
antioxidant enzymes activities including superoxide dismutase (SOD), catalase (CAT), glutathione 
peroxidase (GPx), and glutathione reductase (GR) [46,51–54,56–58,88]. Besides, TRF also reduced 
oxidative stress markers like 4-HNE and protein carbonyls. These changes occurred concurrently 
with the reduction of nuclear factor erythroid 2-related factor 2 and heme oxygenase-1 signaling in 
skeletal muscle of diabetic mice [46]. Muharis et al. also reported that TRF (72% T3; unknown T3 
composition) possessed radical scavenging capacity in a dose-dependent manner via 1-diphenyl 
picrylhydrazyl (DPPH) antioxidant assay [89]. Moreover, the combination of 0.1 g/kg diet T3 
mixtures (22.4% α-T3, 1.6% β-T3, 20.8% γ-T3, and 10.1% δ-T3) with 0.1 g/kg diet astaxanthin on STZ-
induced diabetic Osteogenic Disorder Shionogi rats significantly reduced the lipid peroxidation in 
the serum and liver but not the urine 8-hydroxy-2'-deoxyguanosine (8-OHdG; biomarker for 
oxidative DNA damage) level [66]. Furthermore, T3 also significantly suppressed diabetes-related 
oxidative DNA damage on leukocytes from diabetic rats [56,58]. In a human study, T3-enriched 
canola oil (200 mg/day) significantly reduced serum MDA level and increased total antioxidant 
capacity of 45 T2DM patients [70]. On the other hand, the supplementation of Palmvitee (1800 
mg/day) and refined palm oil (<0.1% T3) significantly reduced the MDA level of T1DM patients [72]. 
However, supplementation of Palmvitee with a higher level of T3 did not further reduce the MDA 
level, which suggested the antioxidant activity was mostly due to the refined palm oil [72]. 
4.6. Effects of T3 in Diabetic Nephropathy 
Nephroprotective effects of T3 were reported as well, whereby TRF from palm oil and RBO 
[53,54] and T3 mixture [52] were demonstrated to improve the renal function of diabetic animals. The 
evidence on the nephroprotective effects of T3 among diabetes patients remains scarce. In detail, T3 
treatments were shown to increase urea and creatinine clearance, and reduce diabetes-related 
polyuria, hyperalbuminuria, hypercreatinuria, proteinuria, hypercreatinemia, and high blood urea 
nitrogen (BUN) levels in diabetic animal models [52–54]. Besides, T3 mixture suppressed oxidative–
nitrosative stress, inflammation, and cellular damage of kidneys through abolishing STZ-
upregulated TNF-α, transforming growth factor-1β, NF-κB, and caspase-3 activities [52]. In addition, 
histological analysis revealed that both TRF from palm oil and RBO reduced diabetic tubules and 
glomerular damages, tubulointerstitial inflammation and mesangial expansion in the kidney of 
diabetic rats [53,54]. There was downregulation of transforming growth factor β, collagen type IV, 
and fibronectin protein expression with TRF treatments, indicating the improvement of renal fibrosis 
[54]. Furthermore, the potency of TRF palm oil was almost double compared to TRF RBO [54]. This 
was attributed to the higher amount of γ-T3 present in TRF palm oil [53,54]. This is supported by the 
fact that γ-T3 has greater antioxidant activity compared to other T3 isoforms [90]. This further 
emphasizes the crucial role of antioxidant activity of T3 in suppressing diabetic nephropathy. Lastly, 
T3-enriched canola oil (200 mg/day) was tested in one double-blinded RCT on 44 T2DM patients [80]. 
The T3 supplementation significantly reduced urine microalbumin but did not reduce serum NO 
level, urine creatinine level, and urine volume in these T2DM patients [80]. The lack of positive 
changes due to T3 supplementation may be dose-related.  
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4.7. Effects of T3 in Diabetes-Related Cardiovascular Diseases 
Several clinical and epidemiological studies have identified that cardiovascular disease is one of 
the major complications of diabetes mellitus [91,92]. T3 was demonstrated to be beneficial in reducing 
hypertensive and cardiovascular complications in diabetic animal models [56,89]. TRF treatment (200 
mg/kg bw/day; unknown composition) was reported to protect the thoracic aorta from diabetes-
mediated vascular wall alterations in STZ-induced diabetic rats with a significant improvement of 
redox status [56]. Biochemical and histological examination further revealed that TRF also 
suppressed the vascular smooth muscle cell degeneration in the aorta and inhibited the formation of 
electron-dense amorphous material in the aortic media [56]. Muharis et al. also reported that TRF 
(72% T3; unknown composition) was beneficial in hypertension management [89]. TRF incubation 
significantly enhanced the acetylcholine-induced relaxation of aorta rings in spontaneously 
hypertensive rats (SHR) and STZ-induced diabetic Wistar Kyoto rats [89]. The TRF-enhanced 
antihypertensive action could involve the modulation of endogenous NO level, possibly by 
endothelial nitric oxide synthase activity [89]. The beneficial effects of T3 in reducing cardiovascular 
diseases among diabetes patient are still uncertain. From two randomized, double-blinded, placebo-
controlled trials, TRF did not significantly improve the vascular function and systolic and diastolic 
pressures among T2DM patients [73,74]. The beneficial effects of T3 on cardiovascular health of 
diabetes patients remain unclear. 
4.8. Effects of T3 in Diabetic Cataractogenesis 
Diabetes-mediated cataractogenesis may be attributable to the diabetes-induced oxidative–
nitrosative stress, which subsequently led to polyol accumulation [82]. To date, only two studies were 
carried out to investigate the anticataractogenic effect of T3 on diabetic animal models [93,94]. Abdul 
Nasir et al. prepared a T3 mixture (90% δ-T3 and 10% γ-T3) in microemulsion formulation (TTE) or 
liposomal formulation (TTL) [93,94]. Result showed that topical application of drop vehicle (10 µL) 
with 0.02 and 0.03% TTE and TTL marginally but significantly slowed down the progression of 
cataract in galactose diet-induced diabetic rats as indicated by lower ocular opacity index, normalized 
total lens protein, soluble lens protein, insoluble lens protein, and soluble to insoluble lens protein 
ratio [93]. Besides, there is no significant difference between TTE and TTL treatment [93]. In addition 
to this, 0.2% TTE was reported to be not beneficial in preventing diabetic cataract progression. This 
was possibly due to the prooxidant activities of T3 mixture in a very high concentration [93]. In the 
second study, TTE was reported to slow down cataractogenesis in STZ-induced diabetic rats with 
lower lenticular aldose reductase activity, sorbitol level and lenticular NF-κB activation in the eyes 
[94]. TTE treatment was shown to normalize the lenticular ATP level, Na+/K+-ATPase activity, plasma 
membrane Ca2+-ATPase activity, sarcoplasmic/endoplasmic reticulum Ca2+-ATPase activity, and 
calpain 2 activity in the eyes of diabetic rats [94]. Moreover, TTE also improved redox status of 
diabetic rats with an increase of lens GSH content, CAT activity and SOD activity, and lower 
lenticular iNOS level, 3-nitrotyrosine (oxidative stress biomarker), and MDA level [93,94]. Topical 
application of TTE did not prevent STZ-induced weight loss and hyperglycemia in diabetic rats [94]. 
Collectively, it is suggested that antioxidant properties of T3 were crucial to inhibit diabetic 
cataractogenesis.  
4.9. Effects of T3 in Diabetic Neuropathy 
T3 was reported to reduce diabetes-related neuropathy in diabetic rats [51,57]. Oral 
administration of T3 mixture (25, 50, and 100 mg/kg bw/day; unknown composition) dose-
dependently improved the behaviour and memory performances of STZ-induced diabetic rats [57]. 
This T3 mixture also inhibited the STZ-induced upregulation of acetylcholinesterase activity in the 
cerebral cortex of diabetic rat [57]. Besides, this T3 mixture also suppressed inflammation and cell 
death events in several regions of the brains of diabetic rats, attributed to lower expression of TNF-
α, IL-1β, NF-κB (p65 subunit), and caspase-3 levels [57]. Furthermore, oral gavage of another T3 
mixture (100 mg/kg bw/day; 145.6 mg/g α-T3, 11.4 mg/g β-T3, 174.2 mg/g γ-T3, and 128.2 mg/g δ-T3) 
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also significantly suppressed oxidative–nitrosative stress in the sciatic nerves of STZ-induced diabetic 
rats [51]. This T3 mixture improved the nociceptive threshold over STZ-induced thermal 
hyperalgesia, mechanical hyperalgesia and tactile allodynia [51]. Similarly to the earlier study, T3 
mixture also dose-dependently suppressed STZ-upregulated plasma TNF-α, plasma IL-1β, plasma 
transforming growth factor-β, and sciatic nerve caspase-3 expression [51], which might be associated 
to the reduction of cellular damage, cell death and inflammation in diabetic rat brains and nervous 
tissues. Besides, the VENUS study showed that oral supplementation of mixed T3 (400 mg/day) for 
one year did not significantly reduce neuropathic symptoms of diabetes on 229 diabetic patients with 
diabetic peripheral neuropathy syndromes [71]; since all the studies used T3 mixtures [51,57], the lack 
of significant neuroprotective effects of T3 in VENUS trial could be due to the difference in T3 
composition. 
Table 1. Summary of the antidiabetic effects of T3 from human studies. 
T3 Isoform Treatment Condition and Population Main Outcomes References 
Dietary intake of T3 
The risk of diabetes and dietary intake of T3 
was investigated via The Finnish Mobile 
Health Examination survey (cohort study) on 
4504 healthy subjects 
 Only β-T3 was significantly 
associated with lower risk of T2DM 
[68] 
The risk of diabetes and dietary intake of T3 
was investigated via ATBC cohort study on 
25,505 healthy subjects 
 None of the T3 isoforms was 
associated with lower risk of 
diabetes after multivariate 
adjustment 
[69] 
T3 (unknown T3 
composition) 
Oral mixed T3 (400 mg/day) capsules were 
supplied to 229 diabetic patients with diabetic 
peripheral neuropathy syndromes (VENUS 
study) 
 400 mg/day is considered as 
safe to human 
 Improved glycemic control 
 Failed to reduce diabetic 
neuropathic symptoms 
[71] 
Palmvitee (16% T3) 
Palmvitee (1800 mg) or refined palm oil 
capsules were provided to 32 T2DM patients 
for 60 days, followed by 60 days washout 
period and then crossed over the 
supplementation for another 60 days 
 T3-containing Palmvitee 
supplement reduced lipid 
peroxidation but not improving 
patients’ lipid profile and HbA1c 
level 
[72] 
TRF (14.6% α-T3, 2.2% 
β-T3, 38.8% γ-T3, and 
2.4% unidentified T3) 
TRF treatment (6 mg/kg bw/day) was supplied 
to 19 T2DM patients for 60 days (RCT study) 
 Improved several lipid profile 
parameters but had no effect on the 
glycemic status and blood pressure  
[73] 
TRF (24.5% α-T3, 3.5% 
β-T3, 35.4% γ-T3, 12.7% 
δ-T3, and 23.9% α-
tocopherol) 
552 mg/day of TRF capsules was supplied to 86 
T2DM patients with impaired vascular 
function for 8 weeks (RCT study) 
 Increased plasma T3 isoforms 
levels upon supplementation.  
 No effect on inflammation, 
lipid profiles, glucose metabolism, 
vascular function, systolic, and 
diastolic pressure 
[74] 
T3 mixture (13.2% α-T3, 
16.6% γ-T3, 8.6% others 
T3, and 16% α-
tocopherol) 
200 mg/day of T3 mixture was supplied to 44 
T2DM patients for 8 weeks (RCT study) 
 Reduced microalbuminuria 
and hsCRP level 
 Had no effect on serum NO 
level and renal function  
[80] 
200 mg/day of T3 mixture was supplied to 45 
T2DM patients for 8 weeks (RCT study) 
 Reduced fasting blood glucose 
level 
 Increased total antioxidant 
capacity and suppressed lipid 
peroxidation 
[70] 
Abbreviations: ATBC = Alpha-Tocopherol, Beta-Carotene Cancer Prevention study, HbA1c = glycated 
hemoglobin A1, NO = nitric oxide, RCT = randomized controlled trial, T2DM = Type 2 diabetes 
mellitus, T3 = tocotrienol, TRF = tocotrienol-rich fraction, VENUS = The Vitamin E in Neuroprotection 
Study. 
4.10. Effects of T3 on Skeletal Muscle of Diabetic Animals 
In addition, a study reported the beneficial effects of T3 on skeletal muscle of high fat-diet/STZ-
induced diabetic C57BL/6J mice [46]. TRF from palm oil (21.8% α-tocopherol, 1.0% γ-tocopherol, 
23.4% α-T3, and 37.4% γ-T3) was dissolved in olive oil and orally administrated to diabetic mice (100 
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and 300 mg/kg bw) for 12 weeks [46]. The results showed that TRF supplementation (300 mg/kg bw) 
significantly reduced the diabetes-related muscle atrophy via the suppression of skeletal muscle cell 
apoptosis [46]. Besides, TRF also reduced oxidative stress and inflammation of skeletal muscle [46]. 
At the cell signaling level, TRF increased mitochondrial biogenesis by restoring sirtuin 1 (SIRT1) and 
AMPK signaling in skeletal muscle [46].  
Figure 3 summarizes the preclinical and clinical findings of T3 on diabetes. 
 
Figure 3. The beneficial effects of tocotrienol on diabetes from preclinical and clinical studies. 
Abbreviations: ↑ = increase or upregulate, ↓ = decrease or downregulate, AMPK = 5′-adenosine 
monophosphate-activated protein kinase, BUN = blood urea nitrogen, CAT = catalase, GPx= 
glutathione peroxidase, GR = glutathione reductase, HbA1c = glycated hemoglobin, HDL-C = high-
density lipoprotein, hsCRP= high sensitivity-C reactive protein, 4HNE = 4-hydroxynonenal, IL-1β= 
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interleukin 1β, IL-6= interleukin 6, IL-18= interleukin 18, LDL-C = low-density lipoprotein, MCP-1= 
monocyte chemotactic protein-1, MDA= malondialdehyde, NF-κB = nuclear factor-κB, NLRP3= 
nucleotide-binding oligomerization domain-like receptor protein 3, NO = nitric oxide, SIRT1= sirtuin 
1, SOD= superoxide dismutase, T2DM= type 2 diabetes mellitus, TC = total cholesterol, TG = 
triglyceride, TNF-α= tumor necrosis factor-α, VLDL-C = very low-density lipoprotein cholesterol. 
5. Metabolites of T3 and Their Potential Metabolic Effects 
T3 is metabolized in the liver in a manner similar with tocopherols, whereby it undergoes 
omega-hydroxylation mediated by CYP4F2 and CYP3A4, followed by beta-oxidation, and 
conjugation to become water-soluble end products to be excreted though urine or faces [95,96]. In 
HepG2 cell culture, γ-T3 was degraded to γ-carboxyethyl hydroxychroman (CEHC), γ-
carboxydimethyloctenyl hydroxychroman (CMBHC), γ-carboxymethylhexenyl hydroxychroman 
(CMHenHC), γ-carboxydimethyloctenyl hydroxychroman (γ-CDMOenHC), and 
carboxydimethyldecadienyl hydroxychroman (CDMD(en)(2)HC), whereas α-T3 was degraded to α-
CEHC, α-CMBHC, α-CMHenHC, and α-CDMOenHC [97]. An in vitro study, using A59 cell culture, 
and an in vivo study using rodent model, showed that γ-tocopherol and γ-T3 were metabolized to 
13′-carboxychromanol and sulfated 9′-, 11′-, and 13′-carboxychromanol [98]. The long-chain vitamin 
E metabolites and CEHC were shown to have important biological activities. In vitro studies showed 
that α-CEHC reduced TNF-α induced nitrite production in rat aortic endothelial cells and mouse 
microglial culture. α-CEHC and γ-CECH inhibited LPS-induced nitrite efflux and prostaglandin E-2 
production in microglial. These effects were not shared by α- and γ-tocopherol [99]. In neutrophils, 
α-, γ-, and δ-tocopherol as well as α-, γ-, and δ-CEHC inhibited superoxide anion production induced 
by phorbol ester. This was achieved by inhibiting the translocation and activation of protein kinase 
C (PKC). The CEHCs demonstrated stronger inhibitory effects on PKC compared to tocopherols 
[100]. The presence of α- or γ-CEHC together with a-tocopherol also delayed the oxidation of LDL 
better than alpha-tocopherol alone [101]. 9′- and 13′-carboxychromanol generated from vitamin E 
metabolism were proved to be potent inhibitors of cyclooxygenase-2 [102]. 13′-carboxychromanol 
also suppressed leukotriene B4 production in human blood neutrophils and HL-60 cells as well as 
inhibiting human recombinant 5-lipoxygenase activity [103]. α-13′-hydroxy- and α-13′-
carboxychromanol were also shown to reduce oxidized LDL uptake and lipid accumulation in 
human macrophages in vitro by suppressing phagocytosis of oxidized LDL [104]. Thus, these 
metabolites may play an important role in preventing atherosclerosis and the proinflammatory states 
in obesity and diabetes. 
6. Difference in the Metabolic Effect between T3 and Alpha-Tocopherol 
Despite the promising metabolic effects of T3, α-tocopherol is still the most abundant vitamin E 
isoform in the body. Pharmacokinetic studies showed that α-tocopherol was distributed more equally 
in all the lipoprotein fractions and T3 was detected mainly in HDL-cholesterol [105]. Studies 
suggested that α-tocopherol was secreted mainly in chylomicrons and T3 in HDL small particles. 
Thus, T3 was shown to be distributed to adipose-rich tissues, like epididymal fat, perirenal fat, and 
skin, while α-tocopherol was distributed more evenly to all tissues [106]. The presence of the highly 
selective α-tocopherol transfer protein in the liver dictates the higher bioavailability of α-tocopherol 
in the body compared to all vitamin E isoforms [107].  
α-tocopherol exhibits many metabolic activities similar with T3. In terms of adipogenesis, α-
tocopherol was shown to increase thermogenic adipocyte differentiation in mammalian white 
adipose tissues and in 3T3-L1 cell culture [108]. It also suppressed IL-6 production (a 
proinflammatory cytokine) by 3T3-L1 adipocytes induced by LPS without affecting IL-10 (an anti-
inflammatory cytokine) production [109]. However, α-tocopherol failed to alter fat accumulation in 
preadipocytes and differentiated adipocytes [110]. In addition, Wu et al. also demonstrated that α-
tocopherol is 2.5 times less potent in inhibiting the proliferation of 3T3-L1 adipocytes as compared to 
α-T3 [29]. Wong et al. also reported that δ-T3, but not α-tocopherol, significantly reduced total fat 
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mass, abdominal circumference, adiposity index, and retroperitoneal and epididymal fat pads mass 
in high carbohydrate/fat diet-fed rats [19].  
In terms of glucose regulation, α-tocopherol showed promising hypoglycemic effects in animal 
studies, by increasing insulin-secreting cells in the pancreas and insulin production, while reducing 
oxidative products and apoptosis in the pancreas [111,112]. α-tocopherol was less potent as compared 
to T3 mixture in reducing the plasma glucose or insulin levels in diabetic rats [19,52]. However, 
translation of the hypoglycemic effects of α-tocopherol to humans proves to be difficult. The ATBC 
Study showed that α-tocopherol supplementation (50 mg/day) for 5–8 years among Finnish male 
smokers did not alter the incidence of type 2 diabetes (relative risk 0.92 (95% CI 0.79–1.07)) [113]. α-
tocopherol (50 mg/day) also did not prevent macrovascular complications (relative risk 0.84 (95% 
confidence interval (CI) 0.65–1.10)) and total mortality due to diabetes (relative risk 1.00 (95% CI 0.80–
1.25)) among this cohort [114]. A randomized, double-blinded, placebo-controlled trial conducted by 
de Oliveira et al. demonstrated that α-tocopherol supplementation (800 mg/day) alone or in 
combination with lipoic acid (600mg/day) did not alter the lipid profile, glucose, insulin, or HOMA-
IR of type 2 diabetic patients after 16 weeks [115]. Furthermore, a randomized, double-blinded, 
placebo-controlled trial by Wu et al. showed that supplementation of α-tocopherol (500 mg/kg) or 
mixed tocopherols (500 mg/kg, 60% γ-tocopherol) for six weeks increased systolic and diastolic blood 
pressure, pulse pressure and heart rate compared to placebo group in diabetic patients. The plasma 
F2-isoprostanes were reduced but endothelium-dependent and -independent vasodilation were not 
altered with both treatments [116]. These two supplementations also did not alter plasma C-reactive 
protein, IL-6, TNF-α, or MCP-1 in the patients [117]. Only mixed tocopherols decreased stimulated 
neutrophil leukotriene B4 production [117].  
The reason underlying the discrepancies on the biological action of α-tocopherol and T3 is not 
clear. In term of antioxidant activities, the double bonds of T3 enables it to distribute more evenly in 
lipid membrane and disorganize the lipid membrane structure, allowing more interactions with free 
radicals. These factors contribute to its higher free radical scavenging capacities and redox recycling 
efficacy compared to its tocopherol counterpart [118,119]. Maniam et al. showed that palm T3 (100 
mg/kg) significantly reduced lipid peroxidation product and increased GPx activity in the bone of 
normal male rats but α-tocopherol did not show similar effects [120]. Palm T3 (60 mg/kg for two 
months) also improved the plasma SOD, GPx, and reduced lipid peroxidation product in 
ovariectomized rats whereas α-tocopherol did not alter the antioxidant status [121]. Similarly, α-
tocopherol was less potent in reducing the lipid peroxidation product and NO levels, and restoring 
nonprotein thiols, SOD, and CAT levels in STZ-induced diabetic rats as compared with T3 mixture 
[52]. However, the relative antioxidant activity of T3 and α-tocopherol is still debatable because it is 
largely dependent on the environment and the assay used [122]. With respect to inflammation, T3 
also exhibited better anti-inflammatory effects compared to α-tocopherol. T3-enriched fraction and 
γ-T3 (60 mg/kg for 2 months) prevented the increase in IL-1 and IL-6 level but α-tocopherol at the 
same dose only lowered IL-1 level in rats administered with nicotine [123]. In another study, although 
both α-tocopherol and palm T3 (30, 60, and 100 mg/kg for 2 months) reduced circulating IL-6 level, 
only palm T3 suppressed IL-1 level in male rats administered with ferric nitrilotriacetate [124]. In 
addition, molecular analysis revealed that α-tocopherol is not a direct agonist for PPARα as it did not 
enhance the interaction of PPARα with PGC-1α [60]. Besides, γ-T3, but not γ-tocopherol, was 
reported to inhibit TNFα-induced NFκB activation via electrophoretic mobility shift assay (EMSA) 
[43]. Furthermore, T3 mixture produced more pronounced effects in comparison to α-tocopherol in 
reducing the upregulated TNFα, tissue growth factor-1β, NFκB, and caspase-3 levels in the kidneys 
of STZ-induced diabetic rats [52]. In diet-induced obese rats, δ-T3 significantly improved the heart 
and liver structures and functions, while α-tocopherol was reported with no or minimal effects [19]. 
The differential effects of α-tocopherol and T3 on HMGCR and cholesterol synthesis are rather 
established. Shibata et al. showed that α-tocopherol alone did not possess lipid-lowering effect, but 
it suppressed the effect of T3. It did this by lowering the hepatic and adipose concentration of T3 
[125]. A study in chicken showed that a vitamin E mixture containing >30% α-tocopherol significantly 
attenuated the HMGCR-suppressing activity of γ-T3 [126]. A study in male hamsters supplemented 
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with isolated corn oil triglycerides and α-tocopherol showed a worse lipid profile marked by raised 
serum TC, LDL-C, and TG levels. In addition, α-tocopherol at lower dose suppressed (30 ppm diet) 
HMGCR activity but at higher dose (81 ppm diet) stimulated HMGCR activity. Co-supplementation 
of T3 (10 mg) and α-tocopherol (5 mg) also attenuated the inhibition of HMGCR activity [127]. 
7. Conclusion and Perspectives 
The evidence accumulated so far, mostly preclinical, supports the therapeutic role of high doses 
of T3 in preventing or reversing obesity and diabetes, and their multisystemic complications. 
However, it is still far from being used clinically in the management of obese and diabetic patients. 
Several issues need to be resolved prior to its application among patients. Firstly, most researchers 
used naturally derived T3 with varying of compositions and purity in their studies. While this is a 
comprehensible decision due to the high cost involved in extracting individual T3 isoforms from the 
sources, it complicates cross-comparison of the findings between studies. The current evidence shows 
that a mixture richer in γT3 like palm T3 (in contrast to T3 from rice bran) seems to demonstrate better 
effects. Secondly, different T3 dosages have been used in previous studies to assess its anti-obesity 
and antidiabetic effects. This, together with the heterogeneity of the T3 mixtures used, complicates 
the determination of T3 dosage in achieving its optimal therapeutic effects. From the human trials 
conducted, a daily dose of 200 mg has been shown to improve the glycemic status of diabetic subjects 
partially. It should be noted that high-dose T3 is potentially harmful, despite the lack of direct 
evidence in humans. Animal studies showed that high-dose T3 could increase bleeding time and 
induce liver abnormality in animals [128,129]. There is a paucity of human evidence on the 
antidiabetic effects of T3, although animal studies suggested a dose as low as 60 mg/kg could reduce 
fat mass in glucocorticoid-treated rats. Thirdly, the molecular mechanism of T3 in augmenting energy 
expenses of the body is still superficial. Most of the researchers attribute the biological effects of T3 
to its antioxidant and anti-inflammatory properties, but studies have shown that T3 can influence cell 
signaling pathways. T3 can downregulate PPARγ, which is responsible for the differentiation of 
adipocytes. It can also suppress the mevalonate pathway, thereby reducing cholesterol synthesis. 
These limitations and research gaps warrant further studies to validate the function of T3 as an agent 
to combat metabolic disorders in humans. The authors suggest that at the current stage, T3 has the 
greatest potential to be developed as a functional food to be used in conjunction with current obesity 
and diabetes management strategies for the benefits of the patients. 
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